Sitemap
Page Directory
Pages
- Adaptive Immunosequencing
- Adaptive Leadership
- Antibody Therapeutics
- Blog
- CA Privacy Notices
- California Compliance Certification
- Career Listings
- Code of Conduct
- Conferences & Events
- Congress & Data Presentations
- Contact Us
- Cookie Policy
- Corporate Social Responsibility
- Drug Discovery Pipeline
- HIPAA Notice of Privacy Practices
- immuneCODE
- Innovation Timeline
- Licenses and Accreditation
- Media Resources
- Medical Affairs
- Medical Information
- MRD Pipeline
- Notice at Collection
- Online Privacy Policy
- Our Story
- Patents and Trademarks
- Platform
- Powering the Age of Immune Medicine
- Privacy Notice Addendum for Laboratory and Testing Services for Patients Outside of the United States
- Request for Protected Health Information
- Research & Development Applications
- Sitemap
- T-Detect
- Target Discovery
- TCR Therapeutics
- TCR-Antigen Map
- Terms of Service
- The Adaptive Immune System
- Who We Are
Posts
- 3 Things the COVID Pandemic Has Taught Us About Immunity
- A Conversation with Jenny Ahlstrom of Myeloma Crowd about Multiple Myeloma, MRD and the Changing Treatment Landscape
- A Message from Co-Founder and CEO Chad Robins
- A Message from our Chief Executive Officer and Co-Founder
- A Reflection on Blood Cancer Awareness Month: Patient Spotlight
- A Testing Renaissance
- Adaptive Computational Biologist Rachel Gittelman on her 2021 STAT Wunderkind Induction
- Adaptive President Julie Rubinstein Reflects on World Cancer Day
- Among Multiple Myeloma Patients Receiving MRD Testing, Majority Report Meaningful Benefits
- An HQ with a View
- Announcing ImmuneRACE – A Call to Patients and Survivors to Help Us Crack the Code to COVID-19
- At Adaptive, Pride Is in Our DNA
- Celebrating Our Lab Professionals During Medical Laboratory Professionals Week – and Every Week
- CEO Chad Robins on accelerating diagnostics and therapeutics to curb COVID-19
- CEO Chad Robins on Expanded Partnership with Microsoft to Decode Covid-19 Immune Response
- CEO Chad Robins on Strategic Partnership with Amgen to Develop Therapeutic Antibodies Against COVID-19
- Clinician Attitudes are Shifting on MRD-guided Decision Making in Multiple Myeloma
- Extending Our Immune Medicine Platform: How T Cells Can Be Used in the Design and Development of Next-Generation Vaccines
- FAQ: Adaptive’s Partnership with Amgen to Find the “Michael Jordan” of COVID-19 Antibodies
- For Multiple Myeloma Patients, Minimal Residual Disease Monitoring Is Ready for Prime Time
- Hope restored: The critical role that Minimal Residual Disease can play in blood cancer patient care
- How Blending Novel Technologies, Big Data and Bright Minds Are Cracking the Code on COVID-19
- Immune Medicine in Action: How Adaptive Immunosequencing Helped Validate a Personalized Vaccine Trial in PDAC
- Introducing Sustainability @ Adaptive
- It’s more than a number: Pride co-leader Shay Miller on the impact of Adaptive’s high marks on the HRC Corporate Equality Index
- Learnings from the COVID-19 Immune Response Will Accelerate Healthcare Innovation
- Molecular Laboratory Operations: The Heartbeat of Adaptive
- MRD in Action: Q&A with Dr. Luciano Costa on the MASTER Trial at ASH 2021
- My Life as a Care Partner: A Perspective by Diane Kennedy
- New Minimal Residual Disease (MRD) Research is Great News for Blood Cancer Patients
- New T-Detect COVID Test Shows the Power of Combining Adaptive’s Immune Medicine Platform with Microsoft’s AI and Machine Learning
- Powering the Age of Immune Medicine
- Reclaiming Women’s Progress Post-Pandemic
- Remaining Vigilant Against COVID-19 and Future Pandemics Means Opening Our Eyes to the T-Cell Immune Response
- Senior Vice President Charles Sang on Expanded FDA Clearance of clonoSEQ® in CLL
- SPIN Girls Field Day Retrospective
- T Cell Testing Outperforms Antibody Testing in Determining Prior COVID-19 Infection
- T Cells: The Unsung Heroes of the Immune System
- Tackling Barriers to MRD Adoption in the Community Setting
- The Adaptive Internship Experience: A Perspective from Sydney W
- The Case for T-cells: Understanding Exposure and Immunity to COVID-19
- The Other Side of The Story: Vaccines Must Produce Both Antibodies and T cell Immunity
- This September, Recognizing Progress in Childhood Blood Cancer Treatment
- Whatever Happens, the Patient Has to be at the Center